References
- Wu O, Robertson L, Langhorne P, et al. Oral contraceptives, hormone replacement therapy, thrombophilias and risk of venous thromboembolism: a systematic review. The Thrombosis Risk and Economic Assessment of Thrombophilia Screening (TREATS) Study. Thromb Haemost 2005; 94: 17–25
- McCann M F, Potter L S. Progestogen-only oral contraception: a comprehensive review. Contraception 1994; 50(Suppl 1)S1–S198
- Hatcher R A, Guillebaud J. The Pill: Combined oral contraceptives. Contraceptive technology17th edn, R A Hatcher, et al. Ardent Media, Inc., New York 1998; 405–460
- Silberstein S D. Hormone-related headache. Med Clin North Am 2001; 85: 1017–1035
- Chi I. The safety and efficacy of progestin-only contraceptives—An epidemiological perspective. Contraception 1993; 47: 1–21
- Fotherby K, Caldwell A DS. New progestogens in oral contraception. Contraception 1994; 49: 1–32
- Kloosterboer H J, Vonk-Noordergraaf C A, Turpijn E W. Selectivity in progesterone and androgen receptor binding of progestagens used in oral contraceptives. Contraception 1988; 38: 325–332
- Rice C F, Killick S R, Dieben T, et al. A comparison of the inhibition of ovulation achieved by desogestrel 75 mcg and levonorgestrel 30 mcg daily. Hum Reprod 1999; 14: 982–985
- Korver T, Klipping C, Heger-Mahn D, et al. Maintenance of ovulation inhibition with the 75 μg desogestrel-only contraceptive pill after scheduled 12-hour delays in tablet-intake. Contraception 2005; 71: 8–13
- Korver T, Dieben T, Vree M, et al. A double-blind study comparing the contraceptive efficacy, acceptability and safety of two progestogen-only pills containing desogestrel 75 mcg/day or levonorgestrel 30 mcg/day. Eur J Contracept Reprod Health Care 1998; 3: 169–178
- Dawood M Y. Primary dysmenorrhea: advances in pathogenesis and management. Obstet Gynecol 2006; 108: 428–441
- Proctor M L, Roberts H, Farquhar C M. Combined oral contraceptive pill (OCP) as treatment for primary dysmenorrhea. Cochrane Database Syst Rev 2001, 4, CD002120
- Bieglmayer C, Hofer G, Kainz C, et al. Concentrations of various arachidonic acid metabolites in menstrual fluid are associated with menstrual pain and are influenced by hormonal contraceptives. Gynecol Endocrinol 1995; 9: 307–312
- Hendrix S L, Alexander N J. Primary dysmenorrhoea treatment with a desogestrel-containing low-dose oral contraceptive. Contraception 2002; 66: 393–399
- Edelman A, Gallo M F, Nichols M D, et al. Continuous versus cyclic use of combined oral contraceptives for contraception: Systematic Cochrane review of randomised controlled trials. Hum Reprod 2006; 21: 573–578
- Wiegratz I, Kuhl H. Long-cycle treatment with oral contraceptives. Drugs 2004; 64: 2447–2462
- Lay C L, Mascellino A M. Menstrual migraine: diagnosis and treatment. Curr Pain Headache Rep 2001; 5: 195–199
- Redmond G, Godwin A J, Olson W, et al. Use of placebo controls in an oral contraceptive trial: methodological issues and adverse event incidence. Contraception 1999; 60: 81–85
- Fraser I S. The promise and performance of progestogens as contraceptives. Reprod Fertil Dev 2001; 13: 713–721
- Porter C, Rees M CP. Bleeding problems and progestogen-only contraception. J Fam Plann Reprod Health Care 2002; 28: 178–181
- Collaborative Study Group on the desogestrel-containing progestogen-only Pill. A double-blind study comparing the contraceptive efficacy, acceptability and safety of two progestogen-only pills containing desogestrel 75 mcg/day or levonorgestrel 30 mcg/day. Eur J Contracept Reprod Health Care 1998; 3: 169–178